Recent investigations into retatrutide, a dual activator for GLP-1 and GIP receptors, are demonstrating significant outcomes in treating weight gain and related non-insulin-dependent disease. Preclinical evidence https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/